Positive Phase 2 Clinical Data With Tivantinib In Hepatocellular Carcinoma - Science 2.0

hihozeima.blogspot.com

Positive Phase 2 Clinical Data With Tivantinib In Hepatocellular Carcinoma Science 2.0 ArQule, Inc. and Daiichi Sankyo, Co., Ltd. (TSE 4568) today announced that an oral presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) will feature Phase 2 trial data with tivantinib as a single agent investigational ... ArQule ready for Phase 3 lung cancer trial Mass High Tech A rQule and Daiichi Sankyo Announce Completion of Patient Recruitment in Phase ... MarketWatch (press release)  »